Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Old hepatitis B virus never dies: It just hides itself within the host genome

Jeong-Hoon Lee

Clin Mol Hepatol. 2021;27(1):107-109. Published online December 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0324

View: 3603 Download: 111 Web of Science: 4 Crossref: 3

Original Article

Spontaneous HBsAg loss in Korean patients: relevance of viral genotypes, S gene mutations, and covalently closed circular DNA copy numbers

Kyun-Hwan Kim, Hye-Young Chang, Jun Yong Park, Eun-Sook Park, Yong Kwang Park, Kwang-Hyub Han, Sang Hoon Ahn

Clin Mol Hepatol. 2014;20(3):251-260. Published online September 25, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.3.251

View: 8751 Download: 77 Web of Science: 7 Crossref: 9

4

A case of sudden-onset hearing Loss in a patient treated with peginterferon α-2b and ribavirin for chronic hepatitis C

Min Ki Shin , Tae Hyo Kim , Kang Ju , Chang Yoon Ha , Hyun Ju Min , Woon Tae Jung , Ok Jae Lee

Clin Mol Hepatol. 2009;15(3):370-374. Published online September 30, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.3.370

View: 4525 Download: 25 Crossref: 3

3

Change of HBV DNA Level as a Predictor of HBeAg Loss after Lamivudine Treatment

Jae Kwon Jung, M.D., Chang Hyeong Lee, M.D., Eun Young Kim, M.D., Jin Tae Jung, M.D., Joon Hyuck Choi, M.D., Ji Min Han, M.D., Myoung In Jin, M.D., Ju Yeon Cho, M.D., Byung Seok Kim, M.D., Im Hee Shin, Ph.D.

Clin Mol Hepatol. 2007;13(4):513-520. Published online December 20, 2007

DOI: https://doi.org/10.3350/kjhep.2007.13.4.513

View: 3650 Download: 28

Pretreatment ALT Level and Histologic Activity as Predictors of HBeAg Loss in Lamivudine Treatment for Chronic Hepatitis B

Young Oh Kweon, M.D. and Kyung Hee Kang, M.D.

Clin Mol Hepatol. 2004;10(1):31-41. Published online January 1, 1970

View: 2551 Download: 14

Loss of Heterozygosity of p73, APC, and p53 in Hepatoblastoma

Han Seong Kim,Young Mi Jung,Mi Ran Kim,Jung Young Lee,Mi Sook Lee,Ja June Jang

Clin Mol Hepatol. 1999;5(1):43-49. Published online January 1, 2000

View: 2090 Download: 13

1 |

Viewed By 5630	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 4850	MAFLD: How is it different from NAFLD?
Viewed By 4608	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3748	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3737	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 135	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 80	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 68	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 57	MAFLD: How is it different from NAFLD?

Search